Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Joseph Z. Ye"'
Autor:
Youram Nassir, Regina A. Swift, Imad A. Tabbara, Joseph Z. Ye, James R. Berenson, Tina Maluso, Shahrooz Eshaghian, Mehdi M. Moezi, Sikander Ailawadhi, Jose Lutzky, Kyle Udd, James Wang, Tanya M. Spektor, Ronald G. Steis, Laura Stampleman, Aleksandra Vidisheva, Jacob D. Bitran
Publikováno v:
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 25(10)
Neuropathy is an important complication that may limit treatment options for patients with multiple myeloma. Previous studies have focused on treatment efficacy and have shown that retreatment with bortezomib (BTZ) is an effective treatment option. T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8efe02655f41649ab161c670f8e79507
https://pubmed.ncbi.nlm.nih.gov/28455546
https://pubmed.ncbi.nlm.nih.gov/28455546
Autor:
Tanya M. Spektor, Steven Jeffrey Hager, Mehdi M. Moezi, Robert A. Moss, Stephen Lim, Shahrooz Eshaghian, Alan Cartmell, Joseph Z. Ye, Tina Maluso, Alberto Bessudo, Regina A. Swift, G. Q. Chen, James R. Berenson, Jacob D. Bitran, Alexa Cohen, Teresa A. Coleman, John Stewart Hrom
Publikováno v:
Journal of Clinical Oncology. 35:8013-8013
8013 Background: The proteasome inhibitor (PI) ixazomib (Ixz) is the first orally administered PI approved for treating multiple myeloma (MM). It has shown clinical activity as a single agent and when used in other combinations. In this phase 1/2 tri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1838bb90754c7d467c112fe440c90ecf
https://doi.org/10.1200/jco.2017.35.15_suppl.8013
https://doi.org/10.1200/jco.2017.35.15_suppl.8013
Autor:
Arthur Baca, Stefanie Mortimer, Rebecca J. Nagy, Joseph Z. Ye, Oliver A. Zill, Razelle Kurzrock, Richard B. Lanman, AmirAli Talasaz, Helmy Eltoukhy, Kimberly C. Banks, Darya Chudova, Coyt Jackson
Publikováno v:
Journal of Clinical Oncology. 34:LBA11501-LBA11501
LBA11501 Background: Next-generation sequencing (NGS) of circulating tumor DNA (ctDNA) enables non-invasive profiling of solid tumor cancers. Liquid biopsy studies to date have been limited to modest-size cohorts and case studies. Methods: Somatic ge
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1bb9391bf7692f248628665d6800747f
https://doi.org/10.1200/jco.2016.34.15_suppl.lba11501
https://doi.org/10.1200/jco.2016.34.15_suppl.lba11501
Autor:
William D. Figg, James A. Zwiebel, Alex Sparreboom, Yusri A. Elsayed, Jane B. Trepel, Joseph Z. Ye, Edward A. Sausville, Manish Monga, Donna Headlee, Anthony J. Murgo, Giovanni Melillo, Mikhail Kalnitskiy, Milin Acharya, Eun Joo Chung, Kyunghwa Hwang, Qin C. Ryan
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 23(17)
Purpose The objective of this study was to define the maximum-tolerated dose (MTD), the recommended phase II dose, the dose-limiting toxicity, and determine the pharmacokinetic (PK) and pharmacodynamic profiles of MS-275. Patients and Methods Patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::067a8c843b92136871814834e15306fe
https://pubmed.ncbi.nlm.nih.gov/15851766
https://pubmed.ncbi.nlm.nih.gov/15851766